Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7380
    -0.0006 (-0.09%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    94,741.59
    -628.92 (-0.66%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6845
    +0.0002 (+0.03%)
     

FUJIFILM (FUJIY) & UCDI to Develop Hydrogen-Oxidizing Bacteria

FUJIFILM Holdings Corporation FUJIY has announced an agreement with the Utilization of Carbon Dioxide Institute or “UCDI” to develop technology for producing organic matter using hydrogen-oxidizing bacteria and carbon dioxide.

The companies are focusing on producing alanine, a type of amino acid, through mass fermentation of UCDI's unique hydrogen-oxidizing bacteria. The collaboration aims to achieve stable mass fermentation of UCDI Hydrogen Bacteria and develop mass production technology for alanine.

Hydrogen-oxidizing bacteria is a type of microorganism that can use carbon dioxide as a source of nutrition and rapidly produce organic matter through a carbon-negative process. This has garnered interest as a potential means of achieving a decarbonized society, which is a pressing issue for the global community.

Fujifilm Holdings Corp. Price and Consensus

Fujifilm Holdings Corp. Price and Consensus
Fujifilm Holdings Corp. Price and Consensus

Fujifilm Holdings Corp. price-consensus-chart | Fujifilm Holdings Corp. Quote

ADVERTISEMENT

UCDI Hydrogen Bacteria possess advanced proliferative ability and can produce various organic matter, including amino acids and alcohol, through genetic modification.

Fujifilm has a history of using production technology, including microbial fermentation and cell culture, to manufacture biopharmaceuticals, and has also developed a next-generation continuous production system for integrated biopharmaceutical production.

In November, FUJIFILM announced an investment of $188 million to build a cell culture media manufacturing facility in North Carolina. The facility will help the company to tap into the growing demand for high-quality cell culture media solutions.

Prior to that, the company announced that it will establish a Japanese Bio-CDMO site in Toyama City to develop vaccines against future pandemics. It is expected to become operational by fiscal 2026. The company is investing ¥90 billion (roughly $850 Million) investment package to accelerate growth of its core Bio CDMO subsidiary.

FUJIFILM expects revenues of ¥2,800 billion for the current year, up from the earlier guidance of ¥2,700 billion, indicating growth of 10.9% year over year. The net income is expected to decline 5.3% year over year to ¥200 billion.

At present, FUJIY carries a Zacks Rank #3 (Hold). The stock has lost 14.2% in the past year compared with the sub-industry’s decline of 32.1%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Stocks to Consider

Some better-ranked stocks from the broader technology space are Arista Networks ANET, Jabil JBL and Super Micro Computer SMCI, each presently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Arista Networks 2022 earnings is pegged at $4.37 per share, up 8.2% in the past 60 days. The long-term earnings growth rate is anticipated to be 17.5%.

Arista Networks’ earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 12.7%. Shares of ANET have declined 18.4% in the past year.

The Zacks Consensus Estimate for Jabil’s 2023 earnings is pegged at $8.31 per share, rising 1.6% in the past 60 days. The long-term earnings growth rate is anticipated to be 12%.

Jabil’s earnings beat the Zacks Consensus Estimate in all the last four quarters, the average being 8.9%. Shares of JBL have declined 3.6% in the past year.

The Zacks Consensus Estimate for Super Micro Computer’s fiscal 2023 earnings is pegged at $9.58 per share, rising 19.8% in the past 60 days.

Super Micro Computer’s earnings beat the Zacks Consensus Estimate in all the last four quarters, the average being 9.4%. Shares of SMCI have soared 83.6% in the past year.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Fujifilm Holdings Corp. (FUJIY) : Free Stock Analysis Report

Jabil, Inc. (JBL) : Free Stock Analysis Report

Super Micro Computer, Inc. (SMCI) : Free Stock Analysis Report

Arista Networks, Inc. (ANET) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research